Ursodeoxycholic acid treatment in a rat model of cancer cachexia

Journal of Cachexia, Sarcopenia and Muscle

Volumn 3, Issue 1, 2012, Pages 31-36

  Tschirner, Anika ^a   von Haehling, Stephan ^a   Palus, Sandra ^a   Doehner, Wolfram ^a   Anker, Stefan D ^a,b   Springer, Jochen ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cancer cachexia; Ursodeoxycholic acid; Wasting; Yoshida hepatoma animal model

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; BROWN ADIPOSE TISSUE; CACHEXIA; CANCER MORTALITY; CONTROLLED STUDY; DRUG MEGADOSE; EXTENSOR DIGITORUM LONGUS MUSCLE; FOOD INTAKE; GASTROCNEMIUS MUSCLE; LEAN BODY WEIGHT; LIVER TUMOR; LOW DRUG DOSE; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; SOLEUS MUSCLE; SURVIVAL; WASTING SYNDROME; WEIGHT REDUCTION;

EID: 84866563812     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0044-4     Document Type: Article

References (25)

1. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1:129-33.
2. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793-9.
3. von Haehling S. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1-5.
4. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381-410.
5. Matthys P, Billiau A. Cytokines and cachexia. Nutrition. 1997;13:763-70.
6. Sharma R, Prichard D, Majer F, Byrne AM, Kelleher D, Long A, et al. Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators. J Med Chem. 2011;54:122-30.
7. Cronin J, Williams L, McAdam E, Eltahir Z, Griffiths P, Baxter J, et al. The role of secondary bile acids in neoplastic development in the oesophagus. Biochem Soc Trans. 2010;38:337-42.
8. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-13.
9. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res. 1998;89:1009-13.
10. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, et al. Chemoprevention of azoxymethaneinduced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994;54:5071-4.
11. Kohno H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitisrelated colon carcinogenesis in mice. Clin Cancer Res. 2007;13:2519-25.
12. Shah SA, Volkov Y, Arfin Q, Abdel-Latif MM, Kelleher D. Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells. Int J Cancer. 2006;118:532-9.
13. Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. Eur J Pharmacol. 2010;640:1-7.
14. Feldman R, Martinez JD. Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta. 2009;1793:1387-94.
15. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998;31:111-8.
16. Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993;92:2783-9.
17. Bauhofer A, Witte K, Celik I, Pummer S, Lemmer B, Lorenz W. Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis. Langenbecks Arch Surg. 2001;386:132-40.
18. Garioud A, Seksik P, Chretien Y, Corphechot C, Poupon R, Poupon RE, et al. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:842-7.
19. Sjoqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Lofberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res. 2004;24:3121-7.
20. Tisdale MJ. Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care. 2008;2:256-61.
21. Shiraki K, Ito T, Sugimoto K, Fuke H, Inoue T, Miyashita K, et al. Different effects of bile acids, ursodeoxycholic acid and deoxycholic acid, on cell growth and cell death in human colonic adenocarcinoma cells. Int J Mol Med. 2005;16:729-33.
22. Byrne AM, Foran E, Sharma R, Davies A, Mahon C, O'Sullivan J, et al. Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells. Carcinogenesis. 2010;31:737-44.
23. Pongracz J, Clark P, Neoptolemos JP, Lord JM. Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer. 1995;61:35-9.
24. Zhang X, Jin B, Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets. 2007;7:305-16.
25. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7-8.